Fig. 2From: Safety assessment of sorafenib in Chinese patients with unresectable hepatocellular carcinoma: subgroup analysis of the GIDEON studyTime to adverse events onset after sorafenib administration in the safety population. a Child-Pugh class A (n = 246). b Child-Pugh class B (n = 38). c Child-Pugh class not evaluable (n = 35). Child-Pugh classes are those at baseline, minimum grade 1. AE: adverse eventsBack to article page